Adaptimmune Therapeutics (ADAP)
(Real Time Quote from BATS)
$1.20 USD
-0.04 (-3.23%)
Updated May 16, 2024 01:21 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Adaptimmune Therapeutics PLC [ADAP]
Reports for Purchase
Showing records 101 - 120 ( 123 total )
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Collaboration With Astellas Validates ADAP''s T-cell Development Expertise
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Updated Phase I Synovial Sarcoma Data Hint At Phase II Success
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Post-Infusion Biomarker Data Correlate With Responses in Synovial Sarcom
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
The Marathon Continues With A Data-Driven Future
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
SITC Is Only 33 Days Away: Abstract Titles Released
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
ESMO Update Increases Our Confidence on ADP-A2M4
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
2Q19 Update - All Programs Moving Forward, More Updates At ESMO 2019
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
SURPASSing The Solid Tumor Challenge With Next-Gen TCRs. Reiterate Buy.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
New CEO Adrian Rawcliffe to Lead Adaptimmune Towards Commercialization
Provider: Roth Capital Partners, Inc.
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
When a Visit Gives You More. Reiterating Our Buy Rating and $7 PT.
Provider: Roth Capital Partners, Inc.
Company: Adaptimmune Therapeutics PLC
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.